Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Dr. Reddys Laboratories (UK) Ltd., 6 Riverview Road, Beverley, East Yorkshire, HU17 0LD, United Kingdom
Lacidipine is indicated in adults for the treatment of hypertension either alone or in combination with other antihypertensive agents, including β-adrenoceptor antagonists, diuretics, and ACE-inhibitors.
The treatment of hypertension should be adapted to the severity of the condition, and according to the individual response.
The recommended initial dose is 2 mg once daily. The dose may be increased to 4 mg (and then, if necessary, to 6 mg) after adequate time has been allowed for the full pharmacological effect to occur. In practice, this should not be less than 3 to 4 weeks. Daily doses above 6 mg have not been shown to be significantly more effective.
Lacidipine should be taken at the same time each day, preferably in the morning.
Treatment with Lacidipine may be continued indefinitely.
Lacidipine is metabolised primarily by the liver and therefore in patients with hepatic impairment, the bioavailability of Lacidipine may be increased and the hypotensive effect enhanced. These patients should be carefully monitored, and in severe cases, a dose reduction may be necessary.
As Lacidipine is not cleared by the kidneys, the dose does not require modification in patients with kidney disease.
The safety and efficacy of Lacidipine in children and adolescents aged below 18 have not been established. No data are available.
For oral administration.
There have been no recorded cases of Lacidipine overdosage. The expected symptoms could comprise prolonged peripheral vasodilation associated with hypotension and tachycardia. Bradycardia or prolonged AV conduction could occur.
There is no specific antidote. Standard general measures for monitoring cardiac function and appropriate supportive and therapeutic measures should be used.
3 years.
This medicinal product does not require any special temperature storage conditions. Store in the original package in order to protect from light.
Alu/Alu blisters (OPA/Alu/PVC-Alu).
Pack sizes: 28
Not all pack sizes may be marketed.
No special requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
